Cargando…

TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer

Tropomyosin receptor kinase (TRK) fusion is one of the oncogenic driver causes of colon cancer, and tropomyosin 3-neurotrophic receptor tyrosine kinase 1 (TPM3-NTRK1) fusion has been detected in the KM12SM cell line. In the present study, we investigated anticancer mechanisms in the KM12SM cell line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohn, Sung-Hwa, Sul, Hee Jung, Kim, Bohyun, Kim, Bum Jun, Kim, Hyeong Su, Zang, Dae Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489125/ https://www.ncbi.nlm.nih.gov/pubmed/34659525 http://dx.doi.org/10.7150/jca.60845

Ejemplares similares

TRK inhibitors in TRK fusion-positive cancers
por: Drilon, A
Publicado: (2019)

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
por: Chen, Yu, et al.
Publicado: (2018)

Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels
por: Sohn, Sung-Hwa, et al.
Publicado: (2020)

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
por: Yang, James C. H., et al.
Publicado: (2022)

Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
por: Rosen, Ezra Y., et al.
Publicado: (2019)

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
por: Waguespack, Steven G, et al.
Publicado: (2022)

Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy
por: Kasi, Pashtoon M, et al.
Publicado: (2022)

Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
por: Klink, Andrew J., et al.
Publicado: (2022)

Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling
por: Sohn, Sung-Hwa, et al.
Publicado: (2020)

TrkA Co-Receptors: The Janus Face of TrkA?
por: Trouvilliez, Sarah, et al.
Publicado: (2023)

Selective activation and down‐regulation of Trk receptors by neurotrophins in human neurons co‐expressing TrkB and TrkC
por: Ateaque, Sarah, et al.
Publicado: (2022)

INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification
por: Sohn, Sung-Hwa, et al.
Publicado: (2019)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer()()
por: Choi, Yuri, et al.
Publicado: (2018)

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
por: Doz, François, et al.
Publicado: (2021)

Blocking TrkB’s Effectors Reveal Benefits of the Road Not Taken
por: Danzer, Steve C.
Publicado: (2019)

Two Trk/Ktr/HKT-type potassium transporters, TrkG and TrkH, perform distinct functions in Escherichia coli K-12
por: Tanudjaja, Ellen, et al.
Publicado: (2022)

Combinatorial Assembly of Small Molecules into Bivalent Antagonists of TrkC or TrkA Receptors
por: Brahimi, Fouad, et al.
Publicado: (2014)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

HEP.TrkX [Vidyo]
por: Anderson, Dustin James
Publicado: (2017)

Signal Transduction Pathways through TRK‐A and TRK‐B Receptors in Human Neuroblastoma Cells
por: Sugimoto, Tohru, et al.
Publicado: (2001)

Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
por: Wong, Derek, et al.
Publicado: (2019)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †
por: Bebb, D. Gwyn, et al.
Publicado: (2021)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
por: Strohmeier, Simon, et al.
Publicado: (2021)

TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions
por: Cappellesso, Rocco, et al.
Publicado: (2022)

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China
por: Xu, Yujun, et al.
Publicado: (2023)

TrkC promotes colorectal cancer growth and metastasis
por: Kim, Min Soo, et al.
Publicado: (2017)

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
por: Sohn, Sung-Hwa, et al.
Publicado: (2022)

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
por: DuBois, Steven G., et al.
Publicado: (2018)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients
por: Perreault, Sébastien, et al.
Publicado: (2021)

TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
por: Bazhenova, Lyudmila, et al.
Publicado: (2021)

Imbalance of neurotrophin receptor isoforms TrkB-FL/TrkB-T1 induces neuronal death in excitotoxicity
por: Vidaurre, Ó G, et al.
Publicado: (2012)

Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists
por: Pankiewicz, Piotr, et al.
Publicado: (2021)

Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers
por: Michels, Renée E., et al.
Publicado: (2022)

TrkA undergoes a tetramer-to-dimer conversion to open TrkH which enables changes in membrane potential
por: Zhang, Hanzhi, et al.
Publicado: (2020)

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
por: Jiang, Tingting, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_thqeue032jci90958f4vahuh32